Aging
Navigate
Submit an Article
Research Paper|Volume 10, Issue 9|pp 2356—2366

A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancer

Ting Lin1,2, Yunong Fu1, Xing Zhang1, Jingxian Gu1, Xiaohua Ma1, Runchen Miao1, Xiaohong Xiang1, Wenquan Niu3, Kai Qu1, Chang Liu1, Qifei Wu4
  • 1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’a, Shaanxi 710061, China
  • 2Department of Surgical Intensive Care Units, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’a, Shaanxi 710061, China
  • 3Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China
  • 4Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’a, Shaanxi 710061, China

* * Equal contribution

Received: July 5, 2018Accepted: September 6, 2018Published: September 11, 2018
https://doi.org/10.18632/aging.101550

Copyright: © 2018 Lin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Non-small cell lung cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. Increasing evidence suggested that the long non-coding RNAs (lncRNAs) were involved in cancer-related death. To explore the possible prognostic lncRNA biomarkers for NSCLC patients, in the present study, we conducted a comprehensive lncRNA profiling analysis based on 1902 patients from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets. In the discovery phase, we employed 682 patients from the combination of four GEO datasets (GSE30219, GSE31546, GSE33745 and GSE50081) and conducted a seven-lncRNA formula to predict overall survival (OS). Next, we validated our risk-score formula in two independent datasets, TCGA (n=994) and GSE31210 (n=226). Stratified analysis revealed that the seven-lncRNA signature was significantly associated with OS in stage I patients from both discovery and validation groups (all P<0.001). Additionally, the prognostic value of the seven-lncRNA signature was also found to be favorable in patients carrying wild-type KRAS or EGFR. Bioinformatical analysis suggested that the seven-lncRNA signature affected patients’ prognosis by influencing cell cycle-related pathways. In summary, our findings revealed a seven-lncRNA signature that predicted OS of NSCLC patients, especially in those with early tumor stage and carrying wild-type KRAS or EGFR.